Theriva™ biologics announces presentation at the american society for cell and gene therapy 27th annual meeting

Rockville, md., april 08, 2024 (globe newswire) -- theriva™ biologics (nyse american: tovx), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the presentation of preclinical data demonstrating the potential synergy between lead product candidate, vcn-01 and liposomal irinotecan in a human pancreatic mouse xenograft. data will be featured in a poster presentation at the american society for cell and gene therapy (asgct) 27th annual meeting, being held both virtually and in baltimore from may 7-11, 2024.
TOVX Ratings Summary
TOVX Quant Ranking